Accessibility Menu
Ipsen logo

Ipsen(OTC) IPSEF

Market Cap$9.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)+100%
5 Year+18%
1 Year+2%
1 Month+0%
$111.27
+0.00%
+0.00Today
Ipsen last closing stock price
MetricPriceDate
Last closeUSD 113.132026-07-31
Ipsen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 113.132026-07-16
1 month+0%USD 113.132026-07-01
3 month+1.67%USD 111.272026-04-28
Year to date+1.67%USD 111.272025-12-26
1 year+1.67%USD 111.272025-07-25
3 year+0.25%USD 112.842023-07-27
5 year+17.74%USD 96.082021-06-28
Since inception+99.82%USD 55.682007-10-18

Ipsen Financials at a Glance

Market Cap

$9.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€8.56B

Net Income (TTM)

€1.08B

EPS (TTM)

$7.21

P/E Ratio

15.65

Dividend

$1.86

Beta (Volatility)

-0.02 (Low)

Price

$111.27

Volume

1,435

Open

$111.27

Previous Close

$111.27

Daily Range

$111.27 - $111.27

52-Week Range

$111.27 - $113.13

Estimated Earnings Date

Feb 11, 2027

IPSEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ipsen

Ipsen S.A. is a biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, rare diseases, and neuroscience. With a strong global presence, Ipsen aims to address unmet medical needs through its diverse portfolio of products.

Products and Services
  • Oncology treatments including Somatuline and Cabometyx
  • Rare disease medications like Bylvay and Iqirvo
  • Neuroscience products such as Dysport for migraine treatment
Growth Outlook
  • Recent quarterly revenue reached €1.53 billion, showcasing strong market demand
  • Ongoing clinical trials for innovative therapies may enhance product pipeline
  • Strategic partnerships could expand market reach and accelerate growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of €6.5 billion reflects robust performance
  • Net income margin of 12.07% indicates effective cost management
  • Operating cash flow of €611 million demonstrates strong liquidity position
AI Generated • Jul 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

5,535

CEO

David G. Loew, MBA

Website

www.ipsen.com

Headquarters

Paris, IF 75015, FR

IPSEF Financials

Key Financial Metrics (TTM)

Gross Margin

67.52%

Operating Margin

30.13%

Net Income Margin

12.67%

Return on Equity

11.33%

Return on Capital

14.34%

Return on Assets

6.87%

Earnings Yield

6.39%

Dividend Yield

1.64%

Payout Ratio

25.71%

Stock Overview

Market Cap

$9.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

82.71M

Volume

1.44K

Avg. Volume

188.476

Financials (TTM)

Gross Profit

€6.58B

Operating Income

€2.43B

EBITDA

€2.88B

Operating Cash Flow

€2.36B

Capital Expenditure

-€866.68M

Free Cash Flow

€1.49B

Cash & ST Invst.

€1.97B

Total Debt

€961.76M

Ipsen Performance Analysis

Ipsen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,179,197,3081.8%
20232023-12-31EUR 3,381,189,0486.4%
20242024-12-31EUR 3,678,397,5868.8%
20252025-12-31EUR 4,148,539,68912.8%
Ipsen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31208.1%
Q22025-06-30-20.6%
Q42025-12-31-28.6%
Q22026-06-3042.9%
Ipsen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 8.20-10.5%
20232023-12-31EUR 8.361.9%
20242024-12-31EUR 4.49-46.3%
20252025-12-31EUR 6.0033.8%
Ipsen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3185.5%
Q22025-06-3075.1%
Q42025-12-31-87.0%
Q22026-06-30695.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€2.19B

+149.7%

Gross Profit

€1.75B

+144.2%

Gross Margin

80.13%

N/A

Market Cap

$9.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.69M

N/A

Employees

5,535

N/A

Net Income

€402.50M

+247.0%

EBITDA

€852.52M

+254.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€1.97B

+305.3%

Total Debt

€961.76M

+96.2%

Accounts Receivable

€998.30M

+38.8%

Inventory

€201.00M

-26.3%

Long Term Debt

€702.45M

+97.8%

Short Term Debt

€259.31M

+91.9%

Return on Assets

6.87%

N/A

Return on Invested Capital

21.29%

N/A

Free Cash Flow

€650.72M

+60.0%

Operating Cash Flow

€679.08M

+45.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ESALFEisai Co., Ltd.
$29.90+0.00%
SGIOFShionogi & Co., Ltd.
$18.91+0.00%
AQSTAquestive Therapeutics, Inc.
$4.66+3.67%
GNMSFGenmab A/S
$337.00+0.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About IPSEF

What is the current price of Ipsen?

Ipsen is trading at $111.27 per share.

What is the 52-week range for Ipsen?

Over the past 52 weeks, Ipsen has traded between $111.27 and $113.13.

How much debt does Ipsen have?

As of the most recent reporting period, Ipsen reported total debt of €1.14B.

How much cash does Ipsen have on hand?

Ipsen reported €1.79B in cash and cash equivalents in its most recent financial results.

What is Ipsen’s dividend yield?

Ipsen currently has a dividend yield of 1.64%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services